A stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment: A case report.

Ovarian cancer (OC), one of the most common gynecological cancers, is usually diagnosed at an advanced stage. High-grade serous ovarian cancer (HGSOC) is a histological subtype of OC that accounts for approximately 70% of all OC cases. erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression commonly occurs in HGSOC, accounting for 12.5% of stage III and IV HGSOCs. Currently, there is no established treatment strategy for OC patients with ERBB2 amplification or ERBB2 overexpression. Whether these patients will benefit from ERBB2 inhibitors remains unclear. Herein, we report a patient with metastatic HGSOC carrying ERBB2 amplification and ERBB2 overexpression. Following progression to platinum-based chemotherapy and subsequent antiangiogenic therapies, the patient benefited from late-line pyrotinib treatment, achieving stable disease with a progression-free survival of 9.5 months. Our study provides preliminary clinical evidence supporting pyrotinib as a feasible treatment option for metastatic HGSOC patients with ERBB2 amplification and/or ERBB2 overexpression. Prospective trials of pyrotinib should be conducted in appropriately selected OC populations.